The total sales of medical technology in Europe is €72.6 Billion which signifies nearly 33% of the world market share (€219 Billion). For comparison, the USA has a share of €98.0 Billion (45%), Japan equals €23.1 Billion (11%), China about €3.7 Billion (2%) and Brazil €3.0 Billion (1%).
...read more
Early Uses & Evidence
U.S. device companies gain coverage and momentum with an international product evaluation. In this evaluation, the collection of clinical data and the verification of the clinical safety and performance of a new device is confirmed. We help you to move rapidly, efficiently and safely into early uses and first clinical trials. We provide actual in-country implementation support by clinical and business development specialists with expertise and experience in international medical markets. Together with your team, acroMIS collaborates productively in the implementation of effective clinical development programs to meet the objectives of first early uses and international adoption of your device.
...read more
International Coverage
International coverage provides valuable advice in the commercialization process of a medical device. Early uses and international opportunities guarantee that a device and its application will become an actual clinical reality. Often, smaller international markets allow an innovative device company to learn from early users and collaborators. For example, new applications can be refined, modification suggestions can be made, and accessories can be created which both extend the use, and improve the results, of a new procedure.
...read more
A Free Consultation
Please register and subscribe here (Your First Step). Email us for an initial free telephone consultation.
acroMIS LLC
+1 (650) 336-8641 voicemail
info@acroMIS.com email
User Agreement (PDF 30kb)
More about acroMIS
Does
Your Company Need to Accelerate Clinical and Commercial Milestones?
More than 80 percent
of senior medical device executives participating in a survey* indicated
that economic policy and regulatory changes are making it more attractive
to do clinical work and commercial launches outside the U.S.
The
big issues with medtech investors is early clinical evidence for regulatory
clarity and early comparative effectiveness data for reimbursement clarity.
Haio
Fauser, Principal , Founder and Owner
acroMIS implementation and development:
High-energy and highly competitive executive responsible for the planning
and implementation of global sales, marketing, reimbursement, business
development and education programs through a dedicated effort of all
team members. Responsibilities include and have included: professional
market expansion; sales forecasting; budget planning; establishment
of training programs; identifying and recruiting KOL key accounts; establish
early majority of technology adopters; collaboration with clinical specialists;
organizational planning; management of local pilot clinical studies;
launch of new product programs; execute hiring plans for global sales
expansion; and development of sales and marketing teams in the United
States, Europe, and Asia.
Read
more: 'Launching Your Medical Products In Other Countries' - Executive
Summary (PDF 89KB).
* Source: Industry Survey, FDANews, Newsletter, July 26, 2010,Vol.37
No.29